Liver Cancer
639
103
132
287
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
87 trials with published results (14%)
Research Maturity
287 completed trials (45% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.9%
57 terminated out of 639 trials
83.4%
-3.1% vs benchmark
9%
56 trials in Phase 3/4
30%
87 of 287 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 287 completed trials
Clinical Trials (639)
A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions
Erector Spinae Plane Block Versus Thoracic Epidural Analgesia for Open Liver Resection
Y-90 Treatment Response Using Transarterial Radioembolization
First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
DESTINY-PANTUMOUR04
Collection of Blood From Patients With Cancer
Trop2-targeted immunoPET Imaging of Solid Tumors
Precision Medicine for Liver Tumours With Quantitative Magnetic Resonance Imaging and Whole Genome Sequencing
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
China Metastatic Liver Cancer Clinical Registry Cohort Database
HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology
Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Brodalumab in the Treatment of Immune-Related Adverse Events
CIRSE Registry for SIR-Spheres in France (CIRT-FR)
68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)